Biomarkers Industry Data Book Covers Cardiac Cancer Biomarkers, Non-alcoholic Steatohepatitis Biomarkers, Global Neurological Biomarkers Markets.
The global biomarkers markets combine to account for USD 41.62 billion revenue in 2021, which is expected to reach USD 137.76 billion by 2030, growing at a cumulative rate of 14.2% over the forecast period.
Grand View Research’s biomarkers industry data book is a collection of market sizing forecasts insights, regulatory technology framework, pricing intelligence, competitive benchmarking analyses, and macro-environmental analyses studies. Within the purview of the database, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research.
Cardiac Biomarkers Market Insights
The global cardiac biomarkers market size was valued at USD 13.98 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 14.7% from 2022 to 2030.
The troponin segment held the largest revenue share of over 30.0% in 2021 and is expected to witness the fastest growth during the forecast period. The exponential growth can be attributed to factors such as diagnostic efficiency, specificity, and accurate predictive detection of cardiac events when compared to other tests. The growing prevalence of myocardial infarction and stroke across the globe further boosts the market growth.
Acute coronary syndrome held the largest revenue share of over 50.0% in 2021 as the disease burden is rapidly rising in low- and middle-income countries when compared to high-income countries. Factors such as rapid urbanization and an increase in jobs that are sedentary are driving the disease incidence. Cardiac troponin T and I biomarkers tests have emerged as the prime diagnostic methods employed for the diagnosis of the disease.
The laboratory testing segment held the largest revenue share of over 65.0% in 2021. This can be attributed to the advantages offered by laboratory testing such as high sensitivity, specificity, scalability, and cost-efficiency. Furthermore, these laboratories facilitate the testing of all types of samples. Diagnostic laboratory services are crucial in clinical decision-making.
Non-alcoholic Steatohepatitis Biomarkers Market Insights
The global non-alcoholic steatohepatitis biomarkers market size was estimated at USD 982.15 million in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 23.6% from 2023 to 2030.
The serum biomarkers segment held the largest market share of 32.51% in 2022. The dominance of the segment is attributed to the effectiveness and the wide adoption of serum biomarkers as a NASH diagnosing tool. Furthermore, its use to differentiate between basic steatosis and NASH gives it a competitive edge.
The pharma and CRO industry end-use segment held the largest market share of 40.58% in 2022 and is expected to witness the fastest growth rate over the forecast period. The growth of the market is attributed to the rising prevalence of liver disorders further increasing demand for non-invasive diagnostic tools to detect chronic liver disease.
Access the Global Biomarkers Industry Data Book, 2022 to 2030, compiled with details like market sizing information forecasts, trade data, pricing intelligence, competition benchmarking, macro-environmental analyses, and regulatory technological framework studies
Cancer Biomarkers Market Insights
The global cancer biomarker market size was valued at USD 10.3 billion in the year 2016 and is estimated to reach a value of USD 33.7 billion by 2025, growing with CAGR of 14.3 %.
Based on type, the market is categorized into breast, prostate, colorectal, cervical, liver, and lung. Breast cancer was the largest segment in 2016. Breast, lung, and prostate cancer cumulatively held the revenue share of over 40% in 2016. Increasing awareness about early testing and growing base of target population are the key factors contributing toward dominance.
Based on the biomolecule, the market is further segmented into genetic, epigenetic, metabolic, and proteomic biomarkers. Genetic biomarkers owing to their extensive usage, high-reliability rate, and easier analysis held a significant market share. Over 85% of malignancies are reported to be detected with the help of genetic and proteomic biomarkers.
Cancer biomolecules find application in various fields such as drug discovery and development, diagnostics, and personalized medicine. Diagnostics were the key revenue-generating application of the market pertaining to factors such as increasing development of biomarker-based oncology tests with high specificity and sensitivity.
Neurological Biomarkers Market Insights
The global neurological biomarkers market size was valued at USD 6.1 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 12.9% from 2020 to 2028.
The proteomic segment accounted for the highest revenue share of over 32% in 2020. Genomic biomarkers accounted for the second-largest market share in 2020. Genomic biomarkers present promising opportunities for the development of personalized medicines and diagnostics based on an individual’s specific genetic variations predisposition to the disease.
The Alzheimer’s disease application segment accounted for the largest market share of over 34% in 2020 and is expected to remain dominant during the forecast period. This growth is credited to the high disease burden and availability of products for clinical use, such as imaging biomarkers-amyloid PET tracers for diagnosis.
The hospital hospital laboratories segment accounted for the largest market share of over 38% in 2020. The segment is expected to remain dominant even during the forecast period due to a rise in hospitalization. Furthermore, the ongoing development of healthcare infrastructure is anticipated to enhance the existing hospital facilities. Most of the blood-based biomarker assays are purchased by hospitals and are used in significant volumes.
Biomarkers Market – Global Industry Segmentation
Biomarkers Industry - Segment Analysis, By Type
- Cardiac Biomarkers
- Troponin
- CK-MB
- Myoglobin
- BNP and NT-proBNP
- Others
- Non-alcoholic Steatohepatitis Biomarkers
- Serum Biomarkers
- Hepatic Fibrosis Biomarkers
- Apoptosis Biomarkers
- Oxidative Stress Biomarkers
- Others
- Cancer Biomarkers
- Genetic Biomarkers
- Epigenetic Biomarkers
- Metabolic Biomarkers
- Proteomic Biomarkers
- Others
- Neurological Biomarkers
- Genetic Biomarkers
- Epigenetic Biomarkers
- Metabolic Biomarkers
- Proteomic Biomarkers
- Others
Biomarkers Industry - Segment Analysis, By End-use
- Pharma CRO Industry
- Hospitals
- Diagnostic Labs
- Academic Research Institutes
Order your copy of the Free Sample of “Biomarkers Industry Data Book - Cardiac Cancer Biomarkers, Non-alcoholic Steatohepatitis Biomarkers, Global Neurological Biomarkers Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research
Biomarkers Industry Data Book Regional Outlook
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Australia
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East Africa (MEA)
- South Africa
- United Arab Emirates
- Saudi Arabia
- Rest of MEA
Biomarkers Industry Data Book Competitive Landscape
The market has become intensely competitive, and products must successfully clear rigorous assessments, which puts them at a significant clinical advantage over existing products.
Key players operating in the biomarkers industry are –
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Bio-Rad Laboratories
- Epigenomics AG
- Thermo Fisher Scientific, Inc.
- Siemens Healthineers AG
- Johnson Johnson Services, Inc
- QIAGEN N.V.
Go through the table of content of biomarkers Industry Data Book to get a better understanding of the Coverage Scope of the study
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com/sector-reports-list
